Bactiguard signs global license agreement with Zimmer Biomet

Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization.

“Our new, global partnership has the potential of expanding Bactiguard’s current license business significantly and making a substantial contribution to our license revenues, both in the near term and in a longer perspective. It also confirms the value of the Bactiguard technology in a new application and global context, which makes me both happy and proud,” says Christian Kinch, CEO.

Orthopedic trauma implants with Bactiguard’s infection preventive technology were CE marked in December 2018 and will be used as a reference in the process of obtaining regulatory clearance.

According to the Orthopaedic Industry Annual Report®, the global orthopedics market was valued at USD 51 billion in 2018, where the orthopedic trauma segment accounted for 14 percent of those sales.

In 2018, Zimmer Biomet generated net sales of close to USD 8 billion. For more information about Zimmer Biomet, please visit www.zimmerbiomet.com

About Bactiguard’s license business
Since 1995, Bactiguard has a successful licensing agreement with Becton, Dickinson and Company (previously C.R Bard) in the US. As a result of this successful partnership, more than 170 million Bactiguard coated Foley-catheters have been sold to date, primarily in the US and Japan.

In 2015, a license agreement for Bactiguard coated orthopaedic trauma implants, covering the ASEAN region in South East Asia, was initiated with Vigilenz Medical Devices. The implants were CE marked in December 2018 and have been approved for sales in Malaysia, where clinical evaluations are currently ongoing.

In 2017, a license agreement with Smartwise was signed in another therapeutic area, whereby drugs and other interventional therapies can be targeted and delivered to specific organs, such as the heart, lungs and the brain. This agreement generated up-front license fees of USD 2.5 million and will generate royalties when the advanced vascular injection catheters have received regulatory approval.

In 2018, a combined distribution and license agreement for China was signed with Well Lead Medical, covering the full Bactiguard product portfolio. This agreement generated initial revenues of some SEK 30 million.

The Bactiguard technology is now approved for use in the urinary tract, respiratory tract, bloodstream and on orthopaedic implants. These metal implants are intended to stay in the body for many months, up to several years and sometimes lifelong and the regulatory approval clearly shows that the technology is safe for patients.


This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2019-09-27, at. 07.30.


A telephone conference for investors, analysts and media will be held at 1.00 pm CET today, where CEO Christian Kinch and CFO Cecilia Edström will present the agreement and answer questions. The presentation for the conference call will be available at Bactiguard’s website www.bactiguard.se/en/for-investors/presentations
  
To participate in the conference call, please dial +46 8 566 426 95  


For further information, please contact:
Cecilia Edström, CFO and deputy CEO, cell phone: +46 72 226 23 28  

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com

Tags:

About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com